Two recently discovered genes involved in ALS could reveal the pathways that are central to the neurodegeneration caused by the disease. But as some researchers storm ahead suggesting treatments targeting these genes, others are questioning how relevant the reports are for nonheritable forms of the disease. Virginia Hughes investigates why the new findings seem to have struck a nerve in the ALS community.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Deng, H.X. et al. Nature 477, 211–215 (2011).
Dejesus-Hernandez, M. et al. Neuron 72, 245–256 (2011).
Renton, A.E. et al. Neuron 72, 257–268 (2011).
Rosen, D.R. et al. Nature 362, 59–62 (1993).
Johnson, J.O. et al. Neuron 68, 857–864 (2010).
Neumann, M. et al. Science 314, 130–133 (2006).
Sreedharan, J. et al. Science 319, 1668–1672 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hughes, V. A raw nerve. Nat Med 17, 1333–1335 (2011). https://doi.org/10.1038/nm1111-1333
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1111-1333
This article is cited by
-
Towards Clinical Application of Mesenchymal Stem Cells for Treatment of Neurological Diseases of the Central Nervous System
Journal of Neuroimmune Pharmacology (2013)